The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 26, 2020
Filed:
Mar. 20, 2015
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Universite DE Montpellier, Montpellier, FR;
Centre Hospitalier Universitaire DE Montpellier, Montpellier, FR;
Jérôme Moreaux, Montpellier, FR;
Bernard Klein, Montpellier, FR;
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris, FR;
UNIVERSITE DE MONTPELLIER, Montpellier, FR;
CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, Montpellier, FR;
Abstract
The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G-Gselected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein βi represent the regression β coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=−1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSv) and concluding that the patient will respond to the combination treatment when the HADMS score is higher than the predetermined reference value HADMSor concluding that the patient will not respond to the combination treatment when the HADMS score is lower than the predetermined reference value HADMS.